Sanofi SA (NAS:SNY)
$ 48.29 -0.1 (-0.21%) Market Cap: 121.07 Bil Enterprise Value: 139.04 Bil PE Ratio: 26.55 PB Ratio: 1.57 GF Score: 84/100

Sanofi SA Oncology Strategy and ASCO R&D Investor Event Transcript

Jun 02, 2020 / 02:00PM GMT
Release Date Price: $49.89 (+0.81%)
Operator

Ladies and gentlemen, thank you for standing by. Welcome to Sanofi's Oncology Investor Call. I would now like to turn the call over to Felix Lauscher from Sanofi Investor Relations. Please go ahead, sir.

Felix Lauscher
Sanofi - Head of IR North America & Asia

Good morning, and good afternoon to everyone on the call. Thank you for joining us on the second of 5-part series of interactive webcast events, which will highlight Sanofi's progress in R&D. Event today will focus on our oncology strategy and ASCO updates. As usual, you can find the slides to this call on the Investors page of our website at sanofi.com.

As part of the momentum building around our pipeline, following today, we will host our next R&D investor event on June 11, focused on DUPIXENT. We are also excited to confirm that the nirsevimab Phase IIb data has been submitted and accepted by a peer review journal. The nirsevimab investor event will be scheduled around the planned publication date.

Moving to Slide 2. I would like to remind you that information presented

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot